Product
mRNA-1608
1 clinical trial
1 indication
Indication
Herpes, GenitalClinical trial
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital HerpesStatus: Active (not recruiting), Estimated PCD: 2025-06-04